CD30+ cutaneous lymphoproliferative disorders: The Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma

Journal of the American Academy of Dermatology

Volumn 49, Issue 6, 2003, Pages 1049-1058

  Liu, Howard L ^a   Hoppe, Richard T ^a   Kohler, Sabine ^a   Harvell, Jeff D ^a   Reddy, Sunil ^a   Kim, Youn H ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Department of Radiation Oncology ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD30 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; VINCRISTINE;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE COURSE; DISEASE EXACERBATION; FEMALE; HISTOPATHOLOGY; HUMAN; LARGE CELL LYMPHOMA; LYMPHOMATOID PAPULOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TISSUE SECTION; UNIVERSITY HOSPITAL;

EID: 0345293277     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0190-9622(03)02484-8     Document Type: Article

References (34)

1. de Bruin P, Beljaards R, van Heerde P, Van Der Valk P, Noorduyn L, Van Krieken J, et al. CD30 expression in normal and neoplastic lymphoid tissue: biologic aspects and clinical implications. Leukemia 1995;9:1620-7.
2. Ralfkiaer E, Delsol G, Willemze R, Jaffe E. Primary cutaneous CD30-positive T-cell lymphoproliferative disorders. World Health Organization classification of tumors. Pathology and genetics of tumors of hematopoetic and lymphoid tissues. Lyon (France): IARC Press; 2001. p. 221-4.
3. Macaulay W. Lymphomatoid papulosis: a continuing self-healing eruption, clinically benign-histologically malignant. Arch Dermatol 1968;97:23-30.
4. Van Neer F, Toonstra J, Van Voorst Vader P, Willemze R, Van Vloten W. Lymphomatoid papulosis in children: a study of 10 children registered by the Dutch cutaneous lymphoma working group. Br J Dermatol 2001;144:351-4.
5. Bekkenk M, Geelen F, Van Voost Vader P, Heule F, Geerts M, Van Volten W, et al. Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch cutaneous lymphoma group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood 2000;95:3653-61.
6. Basarab T, Fraser-Andrews E, Orchard G, Whittaker S, Russel-Jones R. Lymphomatoid papulosis in association with mycosis fungoides: a study of 15 cases. Br J Dermatol 1998;139:630-8.
7. + cutaneous lymphoproliferative disorders: a clinico-pathologic study of 65 cases. Am J Surg Pathol 1998;10:1192-202.
8. Paulli M, Berti E, Rosso R, Boveri E, Kindl S, Klersy C, et al. CD30/Ki-1-positive lymphoproliferative disorders of the skin-clinico-pathologic correlation and statistical analysis of 86 cases: a multicentric study from the European organization for research and treatment of cancer cutaneous lymphoma project group. J Clin Oncol 1995;13:1343-54.
9. Tomaszewski M, Lupton G, Krishnan J, May D. A comparison of clinical, morphologic and immunohistochemical features of lymphomatoid papulosis and primary cutaneous CD30(Ki-1)-positive anaplastic large cell lymphoma. J Cutan Pathol 1995;22:310-8.
10. Zirbel G, Gellis S, Kadin M, Esterly N. Lymphomatoid papulosis in children. J Am Acad Dermatol 1995;33:741-8.
11. Christensen H, Thomsen K, Vejlsgaard G. Lymphomatoid papulosis: a follow-up study of 41 patients. Semin Dermatol 1994;13:197-201.
12. el-Azhary RA, Gibson LE, Kurtin P, Pittelkow M, Muller S. Lymphomatoid papulosis: a clinical and histopathologic review of 53 cases with leukocyte immunophenotyping, DNA flow cytometry, and T-cell receptor gene rearrangement studies. J Am Acad Dermatol 1994;30:210-8.
13. Sanchez N, Pittelkow M, Muller S, Banks P, Winkelmann R. The clinicopathologic spectrum of lymphomatoid papulosis: study of 31 cases. J Am Acad Dermatol 1983;8:91-4.
14. Demierre M, Goldberg L, Kadin M, Koh H. Is it lymphoma or lymphomatoid papulosis? J Am Acad Dermatol 1997;36:765-72.
15. Tomaszewski M, Moad J, Lupton G. Primary cutaneous Ki-1 (CD30) positive anaplastic large cell lymphoma in childhood. J Am Acad Dermatol 1999;40:857-61.
16. Brice P, Cazals D, Mounier N, Verola O, Neidhart-Berard A, Remenieras L, et al. Primary cutaneous large-cell lymphoma: analysis of 49 patients included in the LNH87 prospective trial of polychemotherapy for high-grade lymphomas. Leukemia 1998;12:213-9.
17. Beljaards R, Kaudewitz P, Berti E, Gianotti R, Neumann C, Rosso R, et al. Primary cutaneous CD30-positive large cell lymphoma: definition of a new type of cutaneous lymphoma with a favorable prognosis; a European muliticenter study of 47 patients. Cancer 1993;71:2097-104.
18. Krishnan J, Tomaszewski M, Kao G. Primary cutaneous CD30-positive anaplastic large cell lymphoma: report of 27 cases. J Cutan Pathol 1993;20:193-202.
19. Banerjee S, Heald J, Harris M. Twelve cases of Ki-1 positive anaplastic large cell lymphoma of skin. J Clin Pathol 1991;44:119-25.
20. + lymphoproliferative disorders: comparison with anaplastic large-cell lymphoma of nodal origin. Blood 1996;87:3437-41.
21. Harvell J, Vaseghi M, Natkunam Y, Kohler S, Kim Y. Large atypical cells of lymphomatoid papulosis are CD56 negative: a study of 18 cases. J Cutan Pathol 2002;29:88-92.
22. Carbone P, Kaplan H, Musshoff K, Smithers D, Tubiana M. Report of the Committee on Hodgkin's disease staging classification. Cancer Res 1971;31:1860-1.
23. Gehan E. A generalized Wilcoxon test for comparing arbitrarily singly censored samples. Biometrika 1965;52:203-23.
24. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
25. Cox D, Snell E. Analysis of binary data. London: Chapman and Hall; 1989.
26. Paul M, Krowchuk P, Hitchcock M, Jorizzo J. Lymphomatoid papulosis: successful weekly pulse superpotent topical corticosteroid therapy in three pediatric patients. Pediatr Dermatol 1996;13:501-6.
27. Vonderheid E, Sajjadian A, Kadin M. Methotrexate is effective therapy for lymphomatoid papulosis and other primary cutaneous CD30-positive lymphoproliferative disorders. J Am Acad Dermatol 1996;34:470-81.
28. Wyss M, Dummer R, Dommann S, Joller-Jemelka H, Dours-Zimmermann M, Gilliet F, et al. Lymphomatoid papulosis-treatment with recombinant interferon alpha-2a and etretinate. Dermatology 1995;190:288-91.
29. Diamandidou E, Colome-Grimmer M, Fayad L, Duvic M, Kurzrock R. Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis. Blood 1998;92:1150-9.
30. Vergier B, de Muret A, Beylot-Barry M, Vaillant L, Ekouevi D, Chene G, et al. Transformation of mycosis fungoides: clinico-pathological and prognostic features of 45 cases: French study group of cutaneous lymphomas. Blood 2000;95:2212-8.
31. Olsen E, Bunn P. Interferon in the treatment of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 1995;9:1089-107.
32. Duvic M, Hymes K, Heald P, Breneman D, Martin A, Myskowski P, et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 2001;19:376-88.
33. Duvic M, Martin A, Kim Y, Olsen E, Wood G, Crowley C, et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of retractory or persistent early stage cutaneous T-cell lymphoma. Arch Dermatol 2001;137:581-93.
34. French L, Shapiro M, Junkins-Hopkins J, Vittorio C, Rook A. Regression of multifocal, skin-restricted, CD30-positive large T-cell lymphoma with interferon alfa and bexarotene therapy. J Am Acad Dermatol 2001;45:914-8.